Evidence map›Paper›PMID 37088868›Full record

ReviewJournal of clinical laboratory analysis2023

Proxalutamide for the treatment of COVID-19 rebound following Paxlovid treatment: Report of four cases and review of the literature.

Da-Wei Yang, Min-Jie Ju, Hao Wang, Yi-Chen Jia, Xiao-Dan Wang, Hao Fang, Jia Fan

Abstract readReviewCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of clinical laboratory analysis, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Leveraging SARS-CoV-2 Main Protease (MInternational journal of molecular sciences · 2024
    Article
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Da-Wei YangDepartment of Pulmonary and Critical Care Medicine, Shanghai Engineering Research Center of Internet of Things for Respiratory Medicine, Shanghai Key Laboratory of Lung Inflammation and Injury, Shanghai Institute of Infectious Disease and Biosecurity, Zhongshan Hospital Fudan University, Shanghai, China.ORCID https://orcid.org/0000-0002-8928-143X
Min-Jie JuDepartment of Critical Care Medicine, Zhongshan Hospital Fudan University, Shanghai, China.
Hao WangDepartment of Thoracic Surgery, Zhongshan Hospital Fudan University, Shanghai, China.
Yi-Chen JiaDepartment of Urology, Zhongshan Hospital Fudan University, Shanghai, China.
Xiao-Dan WangDepartment of Pulmonary and Critical Care Medicine, Shanghai Engineering Research Center of Internet of Things for Respiratory Medicine, Shanghai Key Laboratory of Lung Inflammation and Injury, Shanghai Institute of Infectious Disease and Biosecurity, Zhongshan Hospital Fudan University, Shanghai, China.
Hao FangDepartment of Anesthesiology, Zhongshan Hospital Fudan University, Shanghai, China.
Jia FanDepartment of Liver Surgery and Transplantation, Key Laboratory of Carcinogenesis and Cancer Invasion of Ministry of Education, Key Laboratory of Medical Epigenetics and Metabolism, Zhongshan Hospital, Institutes of Biomedical Sciences, Liver Cancer Institute, Fudan University, Shanghai, China.

Funding

National Natural Science Foundation of China 81971863National Natural Science Foundation of China 82170110Science and Technology Commission of Shanghai Municipality 20DZ2261200Shanghai Municipal Key Clinical Specialty shslczdzk02201Shanghai Municipal Science and Technology Major Project ZD2021CY001Shanghai Natural Science Foundation 22ZR1444700Shanghai Pujiang Program 20PJ1402400
6 · The paper itself

Abstract

backgroundThe pandemic the coronavirus disease 2019 (COVID-19) has created a global health crisis. Although Paxlovid is recommended for the early-stage treatment of mild-to-moderate COVID-19 in patients at increased risk of progression to severe COVID-19, more and more cases are reported a COVID-19 rebound after Paxlovid treatment. Currently, information on the additional treatment for COVID-19 rebound following Paxlovid treatment is limited. CASE REPORT: Here, we present four cases with COVID-19 who were mild on admission. All cases experienced a COVID-19 rebound and progressed to severe COVID-19, following treatment with Paxlovid (300 mg of nirmatrelvir with 100 mg ritonavir, twice daily for 5 days). After being treated with proxalutamide (300 mg/day), all cases finally turned real-time reverse transcription polymerase chain reaction (RT-PCR) negative.

conclusionOur cases suggested that proxalutamide might be an effective remedial treatment option for patients experiencing a COVID-19 rebound after Paxlovid treatment.

Indexed as

COVID-19Drug CombinationsHumansLactamsLeucineNitrilesOxazolesProlineRecurrenceRitonavirThiohydantoinsDrug CombinationsLactamsLeucinenirmatrelvir and ritonavir drug combinationNitrilesOxazolesProlineproxalutamideRitonavirThiohydantoinscase reportCOVID-19COVID-19 reboundPaxlovidproxalutamide

Identifiers

PMID37088868
PMCPMC10220290

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.